Activation of WNT/b-catenin signaling results in resistance to PI3K/mTOR dual inhibitor in co-existing KRAS and PIK3CA mutant colorectal cancer cells

被引：0
|
作者：
Park, Ye-Lim
Kim, Hwang-Phill
Cheon, Seul-Ki
Kang, Jun-Kyu
Lim, Yoojoo
Song, Sang-Hyun
Han, Sae-Won
Kim, Tae-you
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-5214
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5214
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Tamoxifen instigates uterine cancer development by activating PI3K signaling and supersedes PIK3CA driver mutations
    Kubler, Kirsten
    Nardone, Agostina
    Anand, Shankara
    Gorvich, Daniel
    Droog, Marjolein
    Hermida-Prado, Francisco
    Akshi, Tara
    Feit, Avery S.
    Cohen, Gabriella
    Dackus, Gwen
    Pun, Matthew
    Kuang, Yanan
    Cha, Justin
    Miller, Mendy
    Gibson, William J.
    Paweletz, Cloud P.
    Van Allen, Eliezer M.
    van Leeuwen, Flora E.
    Nederlof, Petra
    Hollema, Harry
    Quang-De Nguyen
    Mourits, Marian J. E.
    Leshchiner, Ignaty
    Stewart, Chip
    Matulonis, Ursula A.
    Zwart, Wilbert
    Maruvka, Yosef E.
    Getz, Gad
    Jeselsohn, Rinath
    CANCER RESEARCH, 2022, 82 (04)
  • [42] Determination of the PI3Kα selective inhibitor alpelisib mechanism of action and efficacy in ER+/ PIK3CA mutant breast cancer preclinical models
    Fritsch, Christine
    Pfister, Estelle
    Ebel, Nicolas
    Guthy, Daniel
    Schnell, Christian
    Hofmann, Francesco
    CANCER RESEARCH, 2018, 78 (13)
  • [43] Novel class I PI3K inhibitor CH5132799: disruption of the activated PI3K signaling in PIK3CA mutants confers potent antitumor efficacy
    Yoshida, M.
    Tanaka, H.
    Tanimura, H.
    Fujii, T.
    Sakata, K.
    Ohwada, J.
    Yoshimura, Y.
    Ishii, N.
    Kondoh, O.
    Aoki, Y.
    EJC SUPPLEMENTS, 2010, 8 (07): : 32 - 32
  • [44] Different PIK3CA activation mutations can lead to distinct signaling mechanisms and EGFR inhibitor sensitivities in colorectal cancer cells
    Wong, Matthew J.
    Wagle, Marie-Claire
    Hampton, Garret
    Yan, Yibing
    CLINICAL CANCER RESEARCH, 2012, 18 (10)
  • [45] SNORD60 promotes the tumorigenesis and progression of endometrial cancer through binding PIK3CA and regulating PI3K/AKT/mTOR signaling pathway
    Wu, Wu
    Chen, Xi
    Liu, Xin
    Bao, Hai-juan
    Li, Qian-hui
    Xian, Jing-yuan
    Lu, Bing-feng
    Zhao, Yang
    Chen, Shuo
    MOLECULAR CARCINOGENESIS, 2023, 62 (04) : 413 - 426
  • [46] A MEK/PI3K/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cells
    Ischenko, Irene
    Petrenko, Oleksi
    Hayman, Michael J.
    ONCOTARGET, 2015, 6 (18) : 15814 - 15827
  • [47] Overcoming resistance to PI3K inhibitors in PIK3CA mutant breast cancer using CDK4/6 inhibition: Results from a combinatorial drug screen
    Vora, S. R.
    Kim, N.
    Costa, C.
    Lockerman, E. L.
    Li, X.
    Chen, Y.
    Cao, A.
    Pinzon-Ortiz, M.
    Liu, M.
    Kim, S.
    Schlegel, R.
    Huang, A.
    Engelman, J. A.
    CANCER RESEARCH, 2013, 73
  • [48] Generation of a novel PIK3CA mutated duodenal cancer mouse model and evaluation of PI3K inhibitor therapeutic effects
    Sugimori, Makoto
    Sugimori, Kazuya
    Kanemaru, Yushi
    Tsuchiya, Hiromi
    Suzuki, Yoshimasa
    Nakamori, Yoshinori
    Onodera, Sho
    Tsuyuki, Sho
    Hirotani, Akane
    Sawada, Atsushi
    Hirasawa, Kingo
    Nozaki, Akito
    Numata, Kazushi
    Kunisaki, Chikara
    Maeda, Shin
    CANCER SCIENCE, 2024, 115 : 1893 - 1893
  • [49] The comparison between dual inhibition of mTOR with MAPK and PI3K signaling pathways in KRAS mutant NSCLC cell lines
    Turacli, Irem Dogan
    Ozkan, Ayla Cihan
    Ekmekci, Abdullah
    TUMOR BIOLOGY, 2015, 36 (12) : 9339 - 9345
  • [50] GDC-0077 is a selective PI3K alpha inhibitor with robust efficacy in PIK3CA mutant hormone-positive breast cancer models
    Edgar, Kyle
    Hong, Rebecca
    Song, Kyung
    Schmidt, Steven
    Hafner, Marc
    Arrazate, Alfonso
    Williams, Erin
    De La Cruz, Cecile
    Oeh, Jason
    Sampath, Deepak
    Staben, Steve
    Friedman, Lori
    CANCER RESEARCH, 2020, 80 (04)
12345